{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:45:34Z","timestamp":1792043134359,"version":"4.4.0"},"reference-count":0,"publisher":"Codon Publications","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergol Immunopathol"],"abstract":"<jats:p>Introduction: Clinical trials and real-life studies have been published showing effectiveness of benralizumab in severe eosinophilic asthmatic patients. The aim of the present study is to describe super-responders to benralizumab in a series of 79 patients who completed at least 1 year of treatment, and to compare super-responders with non super-responders.\nMethods: This is a multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed in eight hospitals under the conditions of routine clinical practice. Patients with zero exacerbations and no oral corticosteroid therapy for asthma were considered super-responders. We analyzed clinical, functional, and inflammatory parameters of selected patients.Results: In all, 50 of the 79 patients (63%) met the super-responder criteria. In addition, 36% of the patients (26\/71) were considered as complete responders to treatment (superresponder + Asthma Control Test [ACT] \u2265 20 + forced expiratory volume in 1 s [FEV1] \u2265 80%). The super-responders were significantly older in age (P = 0.0029), had higher eosinophils count (P = 0.0423), higher proportion of nasal polyps (P = 0.036), and they had less severe disease at baseline. After 1 year of treatment, the super-responders had higher levels of ACT questionnaire (23 vs 19, P = 0.0007) and better percentage of FEV1 (83 vs 75, P = 0.0359).\nConclusion: Almost two of the three patients treated with benralizumab were super-responders after 1 year of treatment and 36% had a complete response. Super-responders were associated with older age, higher eosinophils count, had nasal polyposis as comorbidity, and had less severe disease at baseline. This data illustrated the good real-life response of patients with severe eosinophilic asthma to the treatment with benralizumab.<\/jats:p>","DOI":"10.15586\/aei.v50i6.704","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T17:41:29Z","timestamp":1667324489000},"page":"163-168","source":"Crossref","is-referenced-by-count":13,"title":["Analysis of response of severe eosinophilic asthmatic patients  to benralizumab"],"prefix":"10.15586","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-3939","authenticated-orcid":false,"given":"Juan Carlos","family":"Miralles-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-9438","authenticated-orcid":false,"given":"Rub\u00e9n","family":"And\u00fajar-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Bravo-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6832-1474","authenticated-orcid":false,"given":"Manuel","family":"Castilla-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Flores-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Loreto","family":"Alemany-Franc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-1901","authenticated-orcid":false,"given":"Manuel Jos\u00e9","family":"Pajar\u00f3n-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mora-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Cabrejos-Perotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouhair","family":"El-Molaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Meseguer-Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Avil\u00e9s-Ingl\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-7613","authenticated-orcid":false,"given":"Jos\u00e9","family":"Valverde-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-3055","authenticated-orcid":false,"given":"Virginia","family":"P\u00e9rez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"RE-ASGRAMUR GROUP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","published-online":{"date-parts":[[2022,11,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/704\/1070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/704\/1071","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/704\/1072","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/704\/1070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T17:41:27Z","timestamp":1667410887000},"score":1,"resource":{"primary":{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/view\/704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v50i6.704","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}